Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind, Randomized, Placebo-Controlled Study of MitoQ as Adjunctive Treatment for Patients With Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCT06191965 is registered in ClinicalTrials.gov with Mclean Hospital as lead sponsor.

NCT NCT06191965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06191965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind, Randomized, Placebo-Controlled Study of MitoQ as Adjunctive Treatment for Patients With Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Lead sponsor
Mclean Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 1, 2024
Completion date
January 31, 2027
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, mitochondrial alteration, schizophrenia and related disorders